Docking studies on butenolide derivatives as Cox-II inhibitors

Medicinal Chemistry Research

Volumn 22, Issue 11, 2013, Pages 5536-5544

  Khokra, Sukhbir Lal ^a   Monga, Jyoti ^a   Husain, Asif ^b   Vij, Mohit ^c   Saini, Reetu ^a  

^a KURUKSHETRA UNIVERSITY   (India)

^b HAMDARD UNIVERSITY   (India)

^c Abhilashi College of Pharmacy   (India)

Author keywords

Anti inflammatory; Butenolides; COX II; Docking studies

Indexed keywords

BUTENOLIDE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; NITROGEN;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONFORMATION; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR DOCKING;

EID: 84887440622     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-013-0511-x     Document Type: Article

References (19)

1. Bhandari SV, Dangre SC, Bothara KG, Patil AA, Sarkate AP, Lokwani DK, Gore ST, Deshmane BJ, Raparti VT, Khachane CV (2009) Design, synthesis and pharmacological screening of novel nitric oxide donars containing 1,5-diaryl pyrazolin-3-one as nontoxic NSAIDs. Eu J Med Chem 44(11):4622-4636
2. Boehm JC, Smietana JM (1996) 1-substituted-4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J Med Chem 39:3929-3937
3. en.wikipedia.org/wiki/cyclooxygenase
4. Gupta S (1999) Inhibitory activities of new series of 4,5-diaryl thiadiazoles derivatives on lipopolysaccharides-induced COX-2 expressions. Ind J Pharmacol 31(5):322-332
5. Halgren TA (1999) MMFF VI. MMFF94s option for energy minimization studies. J Comput Chem 20:720
6. Hasel WH, Hendrickson TF, Still WC (1988) A rapid approximation to the solvent accessible surface areas of atoms. Tetrahedron Comput Methodol 1(2):103-116
7. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307-314
8. Husain A, Khan MSY, Hasan SM, Alam MM (2005) 2-Arylidene-4-(4-phenoxy- phenyl)but-3-en-4-olide:synthesis, reaction and biological activity. Eur J Med Chem 40(12):1394-1404
9. Khan MSY, Husain A, Sharma S (2002) Studies on butenolides: 2-arylidene-4-(substituted aryl) but-3-en-4-olides-synthesis, reactions and biological activity. Ind J Chem 41B(10):2160-2171
10. Khannaa IS, Weier RM, Collins PW (1997) 1,2-Diarylpyrrole as selective inhibitors of cyclo-oxygenase-2. J Med Chem 40:1619-1633
11. Li JJ, Anderson GD, Reitz DB (1995) 1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. J Med Chem 38:4570-4578
12. Maestro, version 9.0 (2010) Macromodel version 9.6; Glide version 5.5, Schrodinger, New York, NY, 2010: LigPrep, version5.5, Schrodinger, New York, NY
13. Manivannan F, Prasanna S, Chaturvedi SC (2004) Rationalization of physico-chemical properties of 5,6-diarylthiazolo[3,2-b] 1,2,4-triazoles towards cyclooxygenase-2 (COX-2) inhibition: a QSAR approach. Ind J Biochem Biophys 41:179-183
14. Omar FA, Mahfouz NM, Rahman MA (1996) Design, synthesis and anti-inflammatory activity of some 1,3,4-oxadiazole derivatives. Eur J Med Chem 31:819-825
15. Poulsen A, William A, Lee A, Blanchard S, Teo E, Deng W, Tu N, Tan E, Sun E, Goh KL, Ong WC, Ng CP, Goh KC, Bonday ZJ (2008) Structure based design of aurora A and B inhibitors. J Comput Aided Mol Modeling Des 22(12):897-906
16. Prasanna S, Daga PR, Xie A, Doerksen RJ (2009) Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking. J Comput Aided Mol Modeling Design 23(2):113-127
17. Sandhu JS (2003) Renal effects of selective cyclooxygenase-2 (COX-2) inhibitors. J Ind Acad Clinical Med 4(1):18-20
18. Singh AK, Pandey A, Tewari M, Prakash K, Shukla HS, Pandey HP (2010) A discussion on chemoprevention of oral cancer by selective cyclooxygenase-2 (COX-2) inhibitors. Digest J Nanomat Biostr 5(2):285-295
19. Still WC, Tempczyk A, Hawley RC, Hendrickson T (1990) Semi-analytical treatment of salvation for molecular mechanics and dynamics. J Am Chem Soc 112:6127-6129